Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
REDUCTION OF HIV-1 ANTIGEN PRODUCTION BY PHOSPHATIDYLCHOLINE CONTAINING FORMULATIONS VIA GROWTH-INHIBITION OF HIV-1-INFECTED CELLS
Autore:
WILLER A; HEINZMANN U; MELLERT W; KLEINSCHMIDT A; GOEBEL FD; ERFLE V;
Indirizzi:
GSF MUNICH,INST MOLEK VIROL,INGOLSTADTER LANDSTR 1 W-8042 NEUHERBERG GERMANY GSF MUNICH,INST MOLEK VIROL,INGOLSTADTER LANDSTR 1 W-8042 NEUHERBERG GERMANY GSF MUNICH,INST PATHOL W-8042 NEUHERBERG GERMANY UNIV MUNICH,MED POLIKLIN W-8000 MUNICH 2 GERMANY
Titolo Testata:
Research in experimental medicine
fascicolo: 2, volume: 193, anno: 1993,
pagine: 123 - 135
SICI:
0300-9130(1993)193:2<123:ROHAPB>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
HTLV-III; CYTO-TOXICITY; RAT-CELLS; MEMBRANE; ADENOVIRUS-TYPE-12; PHOSPHOLIPIDS; PERTURBATION; LYMPHOCYTES; SUPPRESSION; EXPRESSION;
Keywords:
HIV-1 INFECTION; HIV-1 THERAPY; PHOSPHATIDYLCHOLINE; HIV-1 RESERVOIR; ELIMINATION OF HIV-1-INFECTED CELLS; PBMC; ANTIGEN PRODUCTION; RAUSCHER-MULV;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
A. Willer et al., "REDUCTION OF HIV-1 ANTIGEN PRODUCTION BY PHOSPHATIDYLCHOLINE CONTAINING FORMULATIONS VIA GROWTH-INHIBITION OF HIV-1-INFECTED CELLS", Research in experimental medicine, 193(2), 1993, pp. 123-135

Abstract

Phosphatidylcholine (PC) and licensed formulations containing PC weretested for their influence on the proliferation and viability of cells permanently infected with HIV-1 (human immunodeficiency virus type 1). PC alone, as well as pharmaceutical formulations containing PC, selectively inhibited the growth of productively infected lymphoid cells. The strongest growth inhibition was observed with formulations containing PC, glycerol and triglyceride together. The growth inhibition wasdose-dependent for HIV-1-infected cells. Additionally, PC-containing formulations dramatically reduced antigen production from peripheral blood mononuclear cells (PBMCs) infected in vitro with HIV-1. In vivo experiments with Rauscher-MuLV-infected mice showed that PC administered either intraperitoneally or orally was able to inhibit Rauscher-virus-induced splenomegaly. PC-containing formulations are currently used in man for supportive therapy at doses, which in vitro induced 50% growth inhibition of HIV-1-infected cells in vitro. Such doses have been used in man without side effects for many years. Thus, PC-containing formulations may be valuable for the treatment of HIV-1-infected individuals.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 06:39:06